Compare GameStop Corp. (GME) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? GameStop Corp. trades at $25.27 (market cap $12.75B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10× GameStop Corp.'s market cap, and GameStop Corp. is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 61 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GME | VRTX | |
|---|---|---|
Market Cap | $12.75B | $127.55B |
Volume | 13,026,993 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $557.96 |
52-Week Low | $17.87 | $407.37 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | $12.03B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $24.58, down 0.73% on the day, with a bullish technical signal from moving averages and strong insider buying. Revenue declined to $3.82B in 2025, but net income improved to $131.3M with a 25.16% net margin. Recent news highlights CEO Ryan Cohen's aggressive share purchases, fueling positive sentiment.
Outlook hinges on execution of the high-margin collectibles pivot and eBay acquisition potential. Risks include revenue volatility and competitive pressures. Analysts are cautious with 55.55% hold ratings, but insider confidence offers a bullish counter-narrative.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
